Latest Revalesio News & Updates
See the latest news and media coverage for Revalesio. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage pharmaceutical company developing neurological treatments
revalesio.com- Headquarters
- Tacoma, United States
- Company type
- Private company
- Number of employees
- 20–50
Latest news about Revalesio
Company announcements
-
Revalesio shares RNS60's positive stroke outcomes
A study in Stroke: Vascular Interventional Neurology shows patients receiving high-dose RNS60 with EVT had shorter hospital stays than EVT alone.
-
Revalesio presents stroke treatment advances with RNS60 at ASENT meeting
Acting CMO Jordan Dubow showcases Phase 2 RESCUE trial data on infarct reduction and outcomes. VP Andreas Kalmas presents post hoc analysis showing shorter hospital stays and higher home discharges.
-
Revalesio presents Phase 2 RESCUE trial analysis at SVIN 2025
The post-hoc analysis highlights RNS60's potential to shorten hospital stays and increase home discharges for stroke patients. Presentation occurs November 21 in Orlando.
-
Revalesio prepares for Phase 3 stroke trial
Inspired by stroke community momentum, they aim to improve patient outcomes from research.
Media coverage
-
Revalesio to Present Advances in Stroke Treatment with RNS60 at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting
Revalesio, a clinical-stage biopharmaceutical company developing treatments for acute and chronic neurological disorders, today announced its participation in the American Society for Experimental Neurotherapeutics (ASENT...
-
Revalesio to Present Phase 3 Trial Design and Post Hoc Analysis of Phase 2 RESCUE Trial of RNS60 in Acute Ischemic Stroke at the SNIS 22nd Annual Meeting
TACOMA, Wash., July 14, 2025 /PRNewswire/ -- Revalesio, a clinical-stage pharmaceutical company developing treatments for acute and chronic neurological disorders, today announced that two abstracts...
-
Revalesio's Investigational RNS60 Extended Survival in Patients with Amyotrophic Lateral Sclerosis (ALS) in Post-Hoc Analysis of Phase 2 Investigator-Sponsored Trial
TACOMA, Wash., Sept. 17, 2024 /PRNewswire/ -- Revalesio, a clinical-stage pharmaceutical company developing treatments for acute and chronic neurological disorders, today announced the publication of...
-
Revalesio Presents Additional Analyses from the Phase 2 RESCUE Clinical Trial for RNS60 in Acute Ischemic Stroke
About Revalesio Revalesio is a clinical-stage pharmaceutical company with a vision to change the future of treatment for acute and chronic neurological disorders. The company's...
Track Revalesio and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Revalesio competitors & trending companies
Browse news for competitors to Revalesio and other trending companies.
Clene
Neurizon Therapeutics
BioArctic
Raya
Prilenia Therapeutics
Origami Therapeutics
QurAlis
Acelot
Herantis Pharma
Vesalic
Mitochon Pharmaceuticals
NRG Therapeutics
NeuroSense Therapeutics
Harness Therapeutics
Canurta Therapeutics
Aperture Therapeutics
Amylyx
Transposon Therapeutics
Sironax
Attentive
Klaviyo
Twilio
Insider One
Zeta Global
Iterable
Braze
Optimove
Bluecore
BlueConic
Amperity
Wero
BLIK
EPI
Swish
Affirm